MTHFR C677T and A1298C polymorphism's effect on risk of colorectal cancer in Lynch syndrome.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 11 2023
Historique:
received: 11 03 2023
accepted: 04 10 2023
medline: 3 11 2023
pubmed: 2 11 2023
entrez: 2 11 2023
Statut: epublish

Résumé

Lynch syndrome (LS) is characterised by an increased risk of developing colorectal cancer (CRC) and other extracolonic epithelial cancers. It is caused by pathogenic germline variants in DNA mismatch repair (MMR) genes or the EPCAM gene, leading to a less functional DNA MMR system. Individuals diagnosed with LS (LS individuals) have a 10-80% lifetime risk of developing cancer. However, there is considerable variability in the age of cancer onset, which cannot be attributed to the specific MMR gene or variant alone. It is speculated that multiple genetic and environmental factors contribute to this variability, including two single nucleotide polymorphisms (SNPs) in the methylenetetrahydrofolate reductase (MTHFR) gene: C677T (rs1801133) and A1298C (rs1801131). By decreasing MTHFR activity, these SNPs theoretically reduce the silencing of DNA repair genes and increase the availability of nucleotides for DNA synthesis and repair, thereby protecting against early-onset cancer in LS. We investigated the effect of these SNPs on LS disease expression in 2,723 LS individuals from Australia, Poland, Germany, Norway and Spain. The association between age at cancer onset and SNP genotype (risk of cancer) was estimated using Cox regression adjusted for gender, country and affected MMR gene. For A1298C (rs1801131), both the AC and CC genotypes were significantly associated with a reduced risk of developing CRC compared to the AA genotype, but no association was seen for C677T (rs1801133). However, an aggregated effect of protective alleles was seen when combining the alleles from the two SNPs, especially for LS individuals carrying 1 and 2 alleles. For individuals with germline pathogenic variants in MLH1, the CC genotype of A1298C was estimated to reduce the risk of CRC significantly by 39% (HR = 0.61, 95% CI 0.42, 0.89, p = 0.011), while for individuals with pathogenic germline MSH2 variants, the AC genotype (compared to AA) was estimated to reduce the risk of CRC by 26% (HR = 0.66, 95% CI 0.53, 0.83, p = 0.01). In comparison, no association was observed for C677T (rs1801133). In conclusion, our study suggests that combining the MMR gene information with the MTHFR genotype, including the aggregated effect of protective alleles, could be useful in developing an algorithm that estimates the risk of CRC in LS individuals.

Identifiants

pubmed: 37914736
doi: 10.1038/s41598-023-44120-8
pii: 10.1038/s41598-023-44120-8
pmc: PMC10620134
doi:

Substances chimiques

Methylenetetrahydrofolate Reductase (NADPH2) EC 1.5.1.20
DNA 9007-49-2
MTHFR protein, human EC 1.5.1.20

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18783

Informations de copyright

© 2023. Crown.

Références

Int J Colorectal Dis. 2010 Feb;25(2):141-51
pubmed: 19669769
J Clin Oncol. 2015 Feb 1;33(4):319-25
pubmed: 25512458
Int J Med Sci. 2019 Jul 22;16(8):1089-1095
pubmed: 31523170
Arch Intern Med. 2004 Dec 13-27;164(22):2429-31
pubmed: 15596632
J Oncol. 2018 Apr 23;2018:3979135
pubmed: 29849630
Am J Hum Genet. 1998 May;62(5):1044-51
pubmed: 9545395
Eur J Hum Genet. 2006 Apr;14(4):390-402
pubmed: 16479259
Eur J Hum Genet. 2007 Aug;15(8):831-6
pubmed: 17473834
Gastroenterology. 2020 Apr;158(5):1326-1333
pubmed: 31926173
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1611-21
pubmed: 12496052
J Natl Cancer Inst. 2010 Feb 3;102(3):193-201
pubmed: 20028993
J Hum Genet. 2007;52(1):73-85
pubmed: 17089070
Cancer Causes Control. 2006 Oct;17(8):1005-16
pubmed: 16933051
Hered Cancer Clin Pract. 2010 May 21;8(1):5
pubmed: 20487569
Tumour Biol. 2012 Dec;33(6):2041-51
pubmed: 22890827
Cancer Sci. 2004 Nov;95(11):908-13
pubmed: 15546509
J Pathol. 2019 Apr;247(5):574-588
pubmed: 30584801
Clin Transl Oncol. 2014 Jul;16(7):623-9
pubmed: 24193867
Gastroenterology. 2004 Jul;127(1):17-25
pubmed: 15236168
Cancer Lett. 2003 Mar 10;191(2):179-85
pubmed: 12618331
Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1753-9
pubmed: 17855693
Gastroenterology. 2014 Aug;147(2):502-26
pubmed: 25043945
Fam Cancer. 2013 Jun;12(2):207-16
pubmed: 23471748
Hered Cancer Clin Pract. 2009 Dec 23;7(1):17
pubmed: 20028567
J Clin Oncol. 2004 Nov 15;22(22):4486-94
pubmed: 15483016
J Mol Med (Berl). 2001 Sep;79(9):522-8
pubmed: 11692165
Gastroenterology. 2008 Aug;135(2):419-28
pubmed: 18602922
Eur J Hum Genet. 2009 May;17(5):629-35
pubmed: 19156174
Nat Genet. 1995 May;10(1):111-3
pubmed: 7647779
Int J Biol Sci. 2012;8(6):819-30
pubmed: 22719222
Clin Colon Rectal Surg. 2012 Jun;25(2):67-82
pubmed: 23730221
Lancet Oncol. 2021 Jul;22(7):1014-1022
pubmed: 34111421
JAMA. 2011 Jun 8;305(22):2304-10
pubmed: 21642682
Pharmacogenetics. 2002 Jun;12(4):339-42
pubmed: 12042673
Biomed Rep. 2013 Sep;1(5):781-791
pubmed: 24649029
Cancer Causes Control. 2002 Apr;13(3):239-48
pubmed: 12020105

Auteurs

Mariann Unhjem Wiik (MU)

Research Unit, Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, Norway.
Department of Medicine, Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, Norway.
Department of Biological Sciences, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

Mia Negline (M)

School of Biomedical Science and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.

Vidar Beisvåg (V)

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
St. Olav's University Hospital, Central Staff, 7006, Trondheim, Norway.

Matthew Clapham (M)

School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.

Elizabeth Holliday (E)

School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.

Nuria Dueñas (N)

Hereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Oncobell Program, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Joan Brunet (J)

Hereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Oncobell Program, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Marta Pineda (M)

Hereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Oncobell Program, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Nuria Bonifaci (N)

Hereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Oncobell Program, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Stefan Aretz (S)

Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.
Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.

Hannah Klinkhammer (H)

Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Bonn, Germany.

Isabel Spier (I)

Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.
Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.

Claudia Perne (C)

Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.

Andreas Mayr (A)

Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.

Laura Valle (L)

Hereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Oncobell Program, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Jan Lubinski (J)

International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.

Wenche Sjursen (W)

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Department of Medical Genetics, St Olavs University Hospital, Trondheim, Norway.

Rodney J Scott (RJ)

School of Biomedical Science and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.
Department of Molecular Genetics, NSW Health Pathology, John Hunter Hospital, Newcastle, NSW, Australia.

Bente A Talseth-Palmer (BA)

Research Unit, Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, Norway. bente.talseth-palmer@newcastle.edu.au.
School of Biomedical Science and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia. bente.talseth-palmer@newcastle.edu.au.
NSW Health Pathology, Newcastle, NSW, Australia. bente.talseth-palmer@newcastle.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH